{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-068672","form_type":"8-K","ticker":null,"cik":"0001832415","company_name":"Better Therapeutics, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.833491+00:00","generated_at":"2026-06-04T17:48:29.310456+00:00","sec_items":["3.01","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Better Therapeutics voluntarily delists from Nasdaq, entire board and top officers replaced by wind-down specialist","bullets":["Nasdaq hearing March 14 led to voluntary delisting; trading suspended March 18, 2024.","All seven directors resigned, including Chairman Frank Karbe, and CEO Karbe stepped down.","CMO Dr. Mark Berman and CPO Kristyn Wynholds terminated from positions.","Craig R. Jalbert appointed sole officer and director; annual compensation $33,333.","Company intends to file Form 15 to suspend SEC reporting obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-068672","json":"https://secwatch.observer/filing/0001193125-24-068672.json","markdown":"https://secwatch.observer/filing/0001193125-24-068672.md","text":"https://secwatch.observer/filing/0001193125-24-068672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/d812144d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T17:48:29.310456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28873207dd","claim":"Dr. Risa Lavizzo-Mourey resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2b8dd9d19b","claim":"Dr. Richard Carmona resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5599d214f9","claim":"Kristyn Wynholds was terminated as Chief Product Officer at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Dr. Mark Berman and Kristyn Wynholds were each notified by the Company of termination of their positions as Chief Medical Officer and Chief Product Officer, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Product Officer"}],"fact_type":"executive_change"},{"claim_id":"8c11894feb","claim":"Geoffrey Parker resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9a916d7839","claim":"Dr. Mark Berman was terminated as Chief Medical Officer at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Dr. Mark Berman and Kristyn Wynholds were each notified by the Company of termination of their positions as Chief Medical Officer and Chief Product Officer, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"b807a59754","claim":"Andrew Armanino resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b8e7befd62","claim":"Craig R. Jalbert was appointed as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c11edaacf2","claim":"Frank Karbe resigned as CEO, President, Treasurer and Secretary at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe resigned from his position as CEO, President, Treasurer and Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"CEO, President, Treasurer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"cb79089cc1","claim":"David Perry resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cc6cd8af9b","claim":"Dr. Elder Granger resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d142094680","claim":"Craig R. Jalbert was appointed as CEO, President, Treasurer, Secretary at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"CEO, President, Treasurer, Secretary"}],"fact_type":"executive_change"},{"claim_id":"df217fa32d","claim":"Frank Karbe resigned as Director at Better Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}